PlantForm signs agreement with Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab cancer dru

Ontario Industry Updates
Written By Viktoriya Shabat
Plantform logo.png

PlantForm Corporation, PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz (Health Ministry of Brazil) announced a collaborative research and development agreement to develop a biosimilar pembrolizumab for the Brazilian market.

"This agreement advances PlantForm's global strategy for biosimilar drug development and manufacturing to increase affordability and access to a wide range of life-saving medications." said Dr. Don Stewart, PlantForm's President and CEO.

Viktoriya Shabat
Previous

Spartan Bioscience files for creditor protection after identifying 'issue' with COVID-19 test
Next

Aspect Biosystems and JSR Corporation Enter Collaboration to Develop Bioprinted Vascularized Tissues for Regenerative Medicine